Perlmutter Cancer Center

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Advanced Solid Tumors
• Age: Between 18 years - 100 years
• Gender: Male or Female

• Other Inclusion Criteria:
  

  1) Patients with metastatic or locally advanced NSCLC who are not candidates for curative surgery or curative radiation. 2) Histologically or cytologically confirmed diagnosis of metastatic or locally advanced HNSCC that is considered not amenable to further therapy with curative intent. 3) Histologically or cytologically confirmed diagnosis of metastatic or locally advanced ESCC that is not amenable for curative intervention. 4) KRAS G12D or KRAS G12V mutation positive metastatic pancreatic adenocarcinoma. 5) KRAS G12D or KRAS G12V mutation positive metastatic colorectal cancer.
  

You may not be eligible for this study if the following are true:

• 1) History (=3 years) or presence of hematological malignancies. 2) History (=3 years) of other cancer that is histologically distinct from the cancers under study, except for cervical carcinoma in situ, ductal carcinoma in situ, prostatic intraepithelial neoplasia, superficial non-invasive bladder tumors, or curatively treated Stage I non-melanoma skin cancer. 3) Known serious allergy to JAB-3312, pembrolizumab, binimetinib, or excipients (e.g., microcrystalline cellulose). 4) History (=6 months before the start of treatment with the study drugs) of severe autoimmune disease (including = Grade 3 or recurrent Grade 2 immune-related AEs of prior immuno-oncology therapy) or autoimmune disorder that requires chronic systemic corticosteroid treatment at immunosuppressive doses (prednisone >10 mg/day or equivalent